Dr. Reddy's Laboratories: Deep Dive into India's Global Pharma Powerhouse

Equity Research Report | NiftyBrief | June 2026

Company Overview

Dr. Reddy's Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations. Founded in 1984 by Dr. Kallam Anji Reddy, the company has grown into one of the world's most respected pharmaceutical firms, with operations spanning over 60 countries.

Listed on the NSE (DRREDDY) and BSE (500124), Dr. Reddy's currently commands a market capitalisation of ₹1,07,704 crore, making it India's second-largest pharma company by market cap. The stock trades at ₹1,290 as of June 1, 2026, having ranged between a 52-week high of ₹1,380 and a low of ₹1,148 over the past year.

The company operates across three core verticals:

• Global Generics — the largest revenue contributor, with products in the US, Europe, India, and emerging markets
• Pharmaceutical Services & Active Ingredients (PSAI) — API manufacturing and custom pharmaceutical services
• Proprietary Products — biosimilars, Novel Therapies (including NRT — Nicotine Replacement Therapy) and differentiated formulations

Dr. Reddy's is part of multiple benchmark indices including Nifty 50, BSE 500, BSE Healthcare, BSE 100, and BSE 200.

Key Financial Highlights (FY2026 — Consolidated)

The company reported consolidated revenue of ₹33,700 crore for FY2026, a modest growth of ~3.2% over the prior year's ₹32,644 crore. The growth deceleration was primarily driven by pricing pressure in the US generics market and increased competition.

Profit & Loss Summary (₹ in Crore):

Key P&L Observations:

• Revenue has more than doubled from ₹15,023 crore in FY2015 to ₹33,700 crore in FY2026, reflecting a CAGR of approximately 7.7%
• Operating profit peaked at ₹8,547 crore in FY2025 before declining sharply to ₹6,454 crore in FY2026 — a drop of 24.5%
• Operating margins (OPM) compressed significantly from 26% in FY2025 to 19% in FY2026, the lowest since FY2018's 16%
• Net profit fell to ₹4,158 crore in FY2026, down 27.4% from ₹5,725 crore in FY2025
• EPS declined from ₹67.77 to ₹50.27, a contraction of 25.8%
• Other income surged to ₹1,372 crore in FY2026, up from ₹1,119 crore in FY2025, partially cushioning the profit decline
• Depreciation increased to ₹2,059 crore in FY2026, reflecting the expanded asset base from acquisitions and capacity additions
• Interest costs rose to ₹374 crore in FY2026, the highest in the 12-year dataset, up from ₹283 crore in FY2025
• Effective tax rate in FY2026 stood at 23%, consistent with FY2025

Quarterly Results: A Deeper Look at Recent Trends

The quarterly data reveals the extent of the margin pressure in recent quarters:

Critical Quarterly Observations:

• Q4 FY2026 (Mar 2026) was a severe outlier: revenue of just ₹7,546 crore against operating profit of only ₹382 crore and an OPM of just 5%
• Net profit collapsed to ₹221 crore in Q4 FY2026, with EPS of just ₹2.65
• Q4 sales declined 11.5% YoY and were significantly below the trailing four-quarter average of ~₹8,425 crore
• This sharp Q4 weakness could reflect one-time charges, inventory write-downs, or significant pricing pressure in the US generics segment
• Expenses in Q4 FY2026 surged to ₹7,164 crore, eating into revenue
• Interest costs in Q4 FY2026 were ₹106 crore, the highest quarterly reading
• Depreciation at ₹557 crore in Q4 FY2026 was also the highest quarterly figure
• Tax was negative 11% in Q4, suggesting deferred tax benefits or credits

The Q4 FY2026 performance is concerning and warrants close monitoring in upcoming quarters. If the weakness is one-time in nature (e.g., legal settlements, inventory adjustments), the company could recover. If structural, it signals deeper challenges in pricing and competitive positioning.

Balance Sheet Strength

Balance Sheet as of March 2026 (₹ in Crore):

Balance Sheet Highlights:

• Total assets expanded to ₹58,123 crore in FY2026, up from ₹48,023 crore in FY2025 — a 21% increase
• Fixed assets surged to ₹22,063 crore, up from ₹18,226 crore, reflecting heavy capex in manufacturing and capacity
• Borrowings nearly doubled from ₹4,677 crore to ₹7,734 crore, increasing financial leverage
• Reserves grew to ₹37,808 crore, reflecting cumulative retained earnings over the years
• Equity capital was marginally higher at ₹84 crore (face value ₹1)
• Book value per share stands at approximately ₹454, implying the stock trades at a P/B of ~2.84x
• CWIP (Capital Work in Progress) declined from ₹2,466 crore to ₹1,460 crore, suggesting some projects have been commissioned
• Investments increased to ₹5,285 crore from ₹4,051 crore

The balance sheet remains healthy overall, though the increasing borrowings need monitoring. Debt-to-equity ratio (Borrowings / [Capital + Reserves]) stands at approximately 0.20x, which is still comfortable. The company has been aggressively investing in capacity, which should drive future growth.

Cash Flow Analysis

Cash Flow Highlights:

• Operating cash flow in FY2026 was a strong ₹5,674 crore, a 22% improvement over FY2025's ₹4,643 crore
• Free cash flow stood at ₹2,004 crore, robust despite heavy capex
• Capital expenditure (Investing outflow) was ₹6,549 crore in FY2026, the highest in the company's history
• CFO/Operating Profit ratio improved to 109% in FY2026 (from 78% in FY2025), indicating healthy cash conversion despite the P&L weakness
• The company has been a consistent free cash flow generator, with cumulative FCF of approximately ₹14,762 crore over the last 8 years
• Financing inflow of ₹829 crore in FY2026 reflects the increase in borrowings to fund capex

The disconnect between strong operating cash flow (₹5,674 crore) and weak reported net profit (₹4,158 crore) in FY2026 is noteworthy. The ₹1,372 crore of other income and non-cash charges like depreciation (₹2,059 crore) explain the gap partially.

Key Financial Ratios

Ratio Observations:

• ROCE dropped sharply to 14% in FY2026 from 23% in FY2025 and 27% in FY2023, reflecting both the profit decline and the expanded capital base
• Inventory days improved to 228 (from 260), suggesting better working capital management
• Debtor days increased slightly to 110 (from 101), possibly due to slower collections in certain geographies
• Days payable declined to 91 from 97, indicating faster payments to suppliers
• The cash conversion cycle improved marginally to 247 days from 264 days
• Working capital days surged to 109, the highest in the dataset, suggesting tightening of working capital efficiency

Return on Equity (ROE):

• 10-Year ROE: 15%
• 5-Year ROE: 17%
• 3-Year ROE: 17%
• Last Year (FY2026): 12%

The decline in ROE from 17% (3-year average) to 12% (FY2026) is a significant deterioration that underscores the near-term challenges facing the company.

Dividend Policy

Dr. Reddy's has maintained a consistent dividend policy, though payout ratios have been modest:

• The current dividend yield stands at 0.62% based on the stock price of ₹1,290
• Average payout over the last 3 years has been approximately 13.2%, which Screener.in flags as low
• The company has prioritised reinvesting profits into R&D, capacity expansion, and acquisitions over shareholder distributions
• At a P/E of 25.7x, the stock is priced for growth but the current yield offers limited income appeal

Valuation Metrics

At the current price of ₹1,290:

• P/E Ratio: 25.7x (based on TTM earnings)
• P/B Ratio: ~2.84x (based on book value of ₹454)
• Market Cap / Sales: ~3.2x
• Dividend Yield: 0.62%
• EV/EBITDA: approximately 15-17x (estimated)
• PEG Ratio: would require growth estimates; at the current depressed earnings, forward P/E is likely lower

Peer Comparison:

Peer Comparison Analysis:

• Dr. Reddy's is the 6th largest pharma company by market cap in its peer set at ₹1,07,704 crore
• Its P/E of 25.67x is lower than Sun Pharma (34.55x), Divi's Lab (66.33x), and Torrent Pharma (66.90x), but higher than Zydus (20.24x) and Lupin (17.95x)
• The Q4 profit decline of 86.14% is the worst among all peers — a significant red flag
• Q4 sales decline of 11.51% is also among the weakest in the peer set
• ROCE of 13.64% is the lowest in the peer group, with peers averaging 18-22%
• The stock appears relatively cheap on P/E compared to larger peers, but the weak near-term performance justifies the discount

Shareholding Pattern

The shareholding pattern as of March 2026 reveals an interesting shift:

Shareholding Insights:

• Promoter holding has been remarkably stable at ~26.6% over the last three years, indicating strong promoter commitment
• FII holdings have declined sharply from 29.13% in Mar 2024 to 21.14% in Mar 2026 — a reduction of nearly 800 basis points, reflecting foreign institutional selling
• DII holdings have surged from 18.31% to 30.72%, more than compensating for FII exits. This is a strong vote of confidence from domestic institutional investors
• Public/retail holdings decreased from 25.73% to 21.27%, suggesting retail investors have also been booking profits or exiting
• Number of shareholders peaked at 4,59,605 in Mar 2025 and marginally decreased to 4,49,665 in Mar 2026

The FII-to-DII transition is a significant structural change. It means the stock's price action is now more influenced by domestic flows (SIP-driven mutual fund buying) than by foreign portfolio flows. This could provide stability but may also limit upside if FIIs continue to exit.

Investment Thesis: Bull and Bear Cases

Bull Case (Positive Factors):

1. Strong Cash Generation: Operating cash flow of ₹5,674 crore and free cash flow of ₹2,004 crore in FY2026 demonstrate the business generates real cash, not just accounting profits
2. Revenue Growth Track Record: From ₹15,023 crore in FY2015 to ₹33,700 crore in FY2026, a ~8% CAGR over a decade
3. Biosimilars Opportunity: Dr. Reddy's is a leading player in the global biosimilars market, which is expected to grow significantly as patents expire
4. Diversified Geography: Present in 60+ countries across the US, Europe, India, and emerging markets, reducing single-market dependency
5. Strong Brand Portfolio in India: 15 brands in the IPM Top 300; #1 position in stemmatological and #2 in vaccines
6. DII Confidence: Domestic institutional investors have increased their stake to 30.72%, signalling long-term conviction
7. Book Value Growth: From ₹17,558 crore reserves in FY2021 to ₹37,808 crore in FY2026 — cumulative retained earnings
8. Capacity Expansion: Fixed assets have nearly tripled from ₹8,206 crore (FY2021) to ₹22,063 crore (FY2026), setting up for future growth
9. Cheap Relative Valuation: At 25.7x P/E, the stock trades at a discount to Sun Pharma (34.55x) and Divi's Lab (66.33x)
10. Consistent Dividend Payer: Dividends paid every year for the last decade, though at modest levels

Bear Case (Risk Factors):

1. Q4 FY2026 Collapse: Net profit of just ₹221 crore (EPS ₹2.65) and OPM of 5% in the latest quarter is alarming
2. FII Exodus: FII holdings fell from 29.13% to 21.14% — over 1,600 crore of foreign selling pressure in two years
3. US Pricing Pressure: The US generics market faces severe pricing headwinds from competition and regulatory challenges
4. Declining ROCE: From 27% in FY2023 to 14% in FY2026 — the expanded capital base isn't generating proportional returns yet
5. Rising Debt: Borrowings tripled from ₹1,347 crore (FY2023) to ₹7,734 crore (FY2026)
6. Margin Compression: OPM dropped from 28% (FY2024) to 19% (FY2026), the steepest decline in the company's modern history
7. Low Dividend Yield: At 0.62%, the stock offers minimal income; the payout ratio of 13.2% is below peer average
8. High Working Capital Days: At 109 days, working capital intensity is at its highest level, tying up cash
9. Peer Underperformance: Dr. Reddy's is the worst performer in its peer set on both sales growth and profit growth in the latest quarter
10. Elevated Depreciation: At ₹2,059 crore (FY2026), up from ₹1,704 crore, the new capacity is yet to deliver proportional revenue

Management and Governance

Dr. Reddy's Laboratories is led by CEO Erez Israeli and has a professional management structure. The promoter family (Reddy family) holds 26.63%, which is a moderate level — indicating the company is professionally managed rather than being tightly family-controlled.

The company has a strong governance track record:

• Regular dividend payments since inception
• Timely financial reporting
• Conservative accounting policies
• Significant investment in R&D (typically 6-7% of revenue)
• Compliance with global regulatory standards across FDA, EMA, and WHO approved facilities

R&D and Pipeline

Dr. Reddy's spends approximately 6-7% of revenue on R&D, which translates to roughly ₹2,000-2,350 crore annually. This investment fuels:

• Generic drug filings: The company has one of the largest ANDA (Abbreviated New Drug Application) pipelines among Indian pharma companies, with hundreds of filings with the US FDA
• Biosimilars pipeline: Multiple biosimilar products in development targeting oncology, immunology, and other therapeutic areas
• Novel therapies: Including the nicotine replacement therapy (NRT) business under the NicoDerm/Niquitin brands
• Complex generics: Focus on difficult-to-manufacture products like injectables, transdermals, and inhalers

Key Risks to Monitor

1. US Regulatory Risk: Any FDA warning letters or import alerts on key manufacturing facilities could significantly impact the US business
2. Currency Risk: With a significant portion of revenue from the US and Europe, INR appreciation could impact reported earnings
3. Patent Litigation: Challenges from innovator companies on generic launches can delay market entry
4. Raw Material Costs: API prices and supply chain disruptions can compress margins
5. Geopolitical Risks: Tariff policies, especially US trade actions on Indian pharma exports, could impact the business model
6. Competition: Intensifying competition from other Indian generics players (Cipla, Lupin, Aurobindo) and Chinese API manufacturers
7. Q4 Sustainability: The extent of the Q4 FY2026 weakness needs clarity — is it one-time or structural?
8. Interest Rate Environment: With ₹7,734 crore in borrowings, higher rates could further increase interest costs

Technical Context

• Current Price: ₹1,290 (as of June 1, 2026)
• 52-Week Range: ₹1,148 – ₹1,380
• The stock is currently at the midpoint of its 52-week range
• Price-to-Book Value: ₹1,290 / ₹454 = 2.84x
• The stock has been range-bound between ₹1,148 and ₹1,380 over the past year
• It has underperformed the broader Nifty 50 index over the last 12 months given the earnings deterioration

Conclusion

Dr. Reddy's Laboratories is at an inflection point. The company has a proven track record of revenue growth (doubling from ₹15,000 crore to ₹33,700 crore in a decade), strong cash generation (FCF of ₹2,004 crore), and a healthy balance sheet (D/E of 0.20x). Its geographic diversification across 60+ countries, leading Indian brands, and growing biosimilars pipeline provide multiple long-term growth levers.

However, the near-term picture is concerning. FY2026 earnings declined 27%, ROCE fell to 14%, and Q4 FY2026 saw an alarming 5% OPM. The FII exodus (from 29% to 21%) and rising debt (₹7,734 crore) add to the caution.

For long-term investors, the current P/E of 25.7x relative to depressed earnings could represent an attractive entry point if the company can restore margins to the 23-28% range seen in FY2023-FY2025. At an OPM of 23%, EPS would be approximately ₹60-65, implying a forward P/E of 20-22x — reasonable for a company of this quality.

For conservative investors, waiting for clarity on Q4 FY2026's drivers and at least one quarter of margin recovery before committing capital would be prudent.

The DII buying surge (30.72% stake) suggests that institutional domestic investors see value at current levels, which provides a floor of sorts. But the stock needs a positive earnings catalyst — a strong Q1 FY2027 quarter could be the trigger for re-rating.